The research focuses on the therapeutic modulation of gut microbiota using bioactive compounds, including probiotics and traditional medicine-derived polysaccharides. The work combines natural product chemistry with in vitro and in vivo disease models to investigate host-microbiota interactions in inflammatory bowel disease (IBD), colitis, and colorectal cancer. By elucidating mechanistic pathways and microbial influences on the tumor microenvironment, they aim to develop targeted interventions for gastrointestinal and metabolic disorders.